Biotech Values

[Titan V]

OncoSec has said they will announce a drug supply partnership "with a multinational" for the registration trial before it begins in Q2. They have said it's either going to be MRK or BMY but BMY has had no involvement with ONCS so far so it has to be MRK.

FWIW, the CEO has said on a recent public event that there could potentially be an exit opportunity for the lead program within 18 months, and on a few other occasions that they have no plans to get this treatment to market alone.